Y-Intercept (HK)
OBIO icon

Y-Intercept (HK)’s Orchestra BioMed OBIO Stock Holding History

Y-Intercept (HK)’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-43,486
Closed -$188K – 1953
2026
Q2 		$188K Buy
+43,486
New +$178K ﹤0.01% 1579
2025
Q3 		– Sell
-45,447
Closed -$122K – 1899
2025
Q2 		$122K Buy
+45,447
New +$133K ﹤0.01% 1518

Other funds holding OBIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Daytona Street Capital
Daytona Street Capital Saint Louis, Missouri $141M AUM 14.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Holos Integrated Wealth
Holos Integrated Wealth Kennett Square, Pennsylvania $223M AUM 9.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Y-Intercept (HK)'s OBIO Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Orchestra BioMed (OBIO) in Q3 2026, closing a stake of 43,486 shares — an estimated $188K sold.

Y-Intercept (HK) first reported a position in OBIO in Q2 2025 and held it in 2 quarters. The position peaked at $188K in Q2 2026. 28 funds tracked by Wall St. Rank hold OBIO as of Q3 2026.

  • Y-Intercept (HK) reported no remaining Orchestra BioMed position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 43,486 Orchestra BioMed shares in Q3 2026, an estimated $188K.
  • Y-Intercept (HK) first reported a position in Orchestra BioMed in Q2 2025 and held it in 2 quarters.
  • Y-Intercept (HK)'s Orchestra BioMed position peaked at $188K in Q2 2026.
  • 28 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.